HKEX Celebrates Third Anniversary Of New Listing Regime Date 61% of HKEX IPO funds raised from New Economy listings in past three years Hong Kong has become Asia’s largest and the world’s second largest biotech fundraising hub, with 31 pre-revenue biotech companies listings 13 new homecoming listings welcomed, raising a total of HK$285.8 billion
Hong Kong Exchanges and Clearing Limited (HKEX) this week celebrates the third anniversary of its New Listing Regime. In 2018, HKEX launched three new chapters in Hong Kong’s listing rules to allow pre-revenue biotech companies, New Economy companies with weighted voting rights (WVR) structures, and qualified overseas listed companies to raise capital in Hong Kong, fuelling a new growth story in Asia’s leading international capital market.